Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions.

This article discusses a case report of a patient with severe epidermolysis bullosa acquisita (EBA), a rare autoimmune disease characterized by auto-antibodies against type-VII collagen. The patient had previously tried various treatments without success, but achieved sustained clinical remission (CR) for 5 years after receiving rituximab infusions. Rituximab, a monoclonal antibody targeting B lymphocytes, has shown promise in inducing long-term remission for patients unresponsive to conventional therapies. The article highlights the patient's improvement in symptoms, decrease in disease activity scores, and improved quality of life following rituximab treatment. This case adds to the existing evidence for rituximab as an effective treatment for severe EBA. [Extracted from the article]